Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., ... & Hutson, P. R. | Clinical Pharmacokinetics | 28 March 2017

LSD instead of 25I-NBOMe: The revival of LSD? A case report

Bodeau, S., Bennis, Y., Régnaut, O., Fabresse, N., Richeval, C., Humbert, L., ... & Lemaire-Hurtel, A. S. | Toxicologie Analytique et Clinique | 27 February 2017

Ayahuasca dimethyltryptamine, and psychosis: a systematic review of human studies

dos Santos, R. G., Bouso, J. C., & Hallak, J. E. | Therapeutic Advances in Psychopharmacology | 23 February 2017

Safety pharmacology of acute MDMA administration in healthy subjects

Vizeli, P., & Liechti, M. E. | Journal of Psychopharmacology | 21 February 2017

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects

Vizeli, P., Schmid, Y., Prestin, K., zu Schwabedissen, H. E. M., & Liechti, M. E. | European Neuropsychopharmacology | 20 January 2017

Ecstasy research: will increasing observational data aid our understanding of MDMA?

Amoroso, T. | The Lancet Psychiatry | 1 December 2016

Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015

Heise, C. W., & Brooks, D. E. | Journal of medical toxicology | 28 November 2016

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. | Neuroscience Bulletin | 22 November 2016

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S., Johnson, M. W., & Griffiths, R. R. | Journal of Psychopharmacology | 17 November 2016

Decision-making in chronic ecstasy users: a systematic review

Betzler, F., Viohl, L., & Romanczuk‐Seiferth, N. | European Journal of Neuroscience | 15 November 2016

Cognitive and behavioural effects induced by social stress plus MDMA administration in mice

García-Pardo, M. P., Roger-Sánchez, C., Rodríguez-Arias, M., Miñarro, J., & Aguilar, M. A. | Behavioural Brain Research | 10 November 2016

A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4 Methylendioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction

Darracq, M. A., Thornton, S. L., Minns, A. B., & Gerona, R. R. | Journal of Psychoactive Drugs | 16 September 2016

Ayahuasca Treatment Center Safety for the Western Seeker

Ray, R. R., & Lassiter, K. S. | Anthropology of Consciousness | 15 September 2016

Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review

Romeo, B., Choucha, W., Fossati, P., & Rotge, J. Y. | L'Encephale | 9 September 2016

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. | Journal of Psychopharmacology | 30 August 2016

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies

Vegting, Y., Reneman, L., & Booij, J. | Psychopharmacology | 28 August 2016

The Psychedelic Policy Quagmire: Health, Law, Freedom, and Society

Van Hagen, A. G. | BJPsych Bull | 11 August 2016

The potential use of ayahuasca in psychiatry

Frecska, E., Bokor, P., Andrassy, G., & Kovacs, A. | Neuropsychopharmacologia Hungarica | 1 June 2016

Using the Theory of Planned Behavior to predict implementation of harm reduction strategies among MDMA/ecstasy users

Davis, A. K., & Rosenberg, H. | Psychology of Addictive Behaviors | 1 June 2016

Ketamine abuse potential and use disorder

Liu, Y., Lin, D., Wu, B., & Zhou, W. | Brain research bulletin | 31 May 2016

Ibogaine and addiction in the animal model, a systematic review and meta-analysis

Belgers, M., Leenaars, M., Homberg, J. R., Ritskes-Hoitinga, M., Schellekens, A. F. A., & Hooijmans, C. R. | Translational psychiatry | 31 May 2016

In reply – on the toxicity of ibogaine

Brunt, T. M., & Litjens, R. P. | Clinical toxicology | 31 May 2016

On the toxicity of ibogaine

Yip, L., & Deng, J. F. | Clinical Toxicology | 31 May 2016

Human Pharmacology of Mephedrone in Comparison to MDMA

Papaseit, E., Pérez-Mañá, C., Mateus, J. A., Pujadas, M., Fonseca, F., Torrens, M., ... & Farré, M. | Neuropsychopharmacology | 20 May 2016

Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat

Horsley, R. R., Lhotkova, E., Hajkova, K., Jurasek, B., Kuchar, M., & Palenicek, T. | Brain Research Bulletin | 4 May 2016